Boston Scientific receives CE Mark for Vercise primary cell DBS system

Boston Scientific has announced that its Vercise primary cell deep brain stimulation (DBS) system has been granted European CE Mark approval.

The device is intended to provide precise neural targeting to address the varying needs of patients suffering from Parkinson's disease, primary and secondary dystonia, and essential tremor.

This non-rechargeable treatment option powers the Vercise DBS Directional Lead, the first commercially available eight-contact segmented lead with current steering. It is also the only DBS solution that finely controls the size and shape of stimulation with multiple independent current control technology.

An evaluation of the system in the European VANTAGE study demonstrated a highly significant and consistent improvement in motor scores, as well as an increase in quality of life.

Maulik Nanavaty, senior vice-president and president for neuromodulation at Boston Scientific, said: "This new system exemplifies the Boston Scientific commitment to advancing DBS therapy and providing impactful and transformative technology to reach a broader range of patients suffering from these debilitating diseases."

This comes after the firm received CE Mark approval for MRI-compatible labelling to be applied to a number of its ICD and CRT-D systems last month.